Premier Alternatives

Auron Therapeutics

Newton, MA · Founded 2018 · Privately Held (backing)

Operator of a biotechnology company intended to research and develop products focusing on the immunology and oncology medical fields. Auron Therapeutics is based in Newton, MA and was founded in 2018. It was valued at $106 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $90.7 million across 4 recorded rounds; the latest was a $27.3 million early-stage round in Dec 2024.

PMV mark · valuation
$106.3M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$90.7M
Last round
Early Stage VC
Dec 2024

Auron Therapeutics key facts

as of Oct 2026
  • Operator of a biotechnology company intended to research and develop products focusing on the immunology and oncology medical fields.
  • Auron Therapeutics is valued at approximately $106.3M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $90.7M across 4 recorded rounds; the latest was Early Stage VC ($27.3M) in Dec 2024.
  • Notable investors include Qiming Venture Partners USA, DCVC, Polaris Partners, Arkin Capital, Casdin Capital — 15 tracked in total.
  • Auron Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently Dec 2024 ($13.4M sold to 15 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$106.3M

Valued at $106.3M at its later-stage round, Dec 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Auron Therapeutics with a free account
  • ·The complete investor list: 15 names
  • ·Watch Auron Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Auron Therapeutics funding rounds

4 rounds
Dec 2024Early Stage VC$27.3MSEC filing▮
Jul 2022Early Stage VC$38.4MSEC filing▮
Dec 2020Early Stage VC$15.4MSEC filing▮
Jun 2018Debt$660KSEC filing▮
Full funding history →

Auron Therapeutics valuation

Auron Therapeutics was valued at $106 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Auron Therapeutics raised?

Auron Therapeutics has raised $90.7 million across 4 recorded rounds since 2018. The largest was a $660,000 debt round in Jun 2018; the most recent was a $27.3 million early-stage round in Dec 2024.

Auron Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently in Dec 2024 ($13.4 million sold to 15 investors).

Auron Therapeutics investors

15 investors are on record for Auron Therapeutics, including Qiming Venture Partners USA, DCVC, Polaris Partners and Arkin Capital. By type, the record holds 6 venture capital firms, 1 family office and 1 asset manager. The early-stage round in Dec 2024 drew 16 investors.

About Auron Therapeutics

Operator of a biotechnology company intended to research and develop products focusing on the immunology and oncology medical fields. The company's research aims to cure cancer by changing the paradigm of cancer therapeutics from cell killing to the transformation of malignant cells into normal functioning cells, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical need and offer life-saving, transformative medicines for cancer patients.

Sector
Healthcare
HQ
Newton, MA, United States
Founded
2018
Employees
23
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.